NCT06510894View on ClinicalTrials.gov

Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression

RecruitingOBSERVATIONAL

Enrollment

40

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Cardiac Sarcoidosis

Interventions

DRUG

Sotagliflozin

Sodium-glucose cotransporter-1/2 inhibitor

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Duke University

All Listed Sponsors

collaborator

Duke University

OTHER

lead

University of Pennsylvania

OTHER

NCT06510894 - Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression | Biotech Hunter | Biotech Hunter